Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

The Guardian - UK

Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble

Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company.

Investors Business Daily

Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges

Shares of Acadia Pharmaceuticals toppled Wednesday after the biotech company's experimental treatment for a rare, genetic disorder failed.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK

Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - as it happened

Spot gold trading just below Monday’s fresh record high

The Guardian - UK

Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback

Shares of Scholar Rock reversed and closed in the green Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

Investors Business Daily

Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff

The Food and Drug Administration approved an injectable version of Merck's biggest moneymaker, cancer behemoth Keytruda.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Novartis Chief Eyes Ways To End Higher US Drug Prices: Media

Amid a threat of towering US tariffs, Swiss pharmaceutical giant Novartis is seeking ways to enable Americans to pay less for their medicines, its chief said in an interview published Saturday.

International Business Times

NHS drug pricing is all about the art of the deal

Letter: Better negotiation with big pharma could ease the process, writes Andrew Dillon, in response to an article by Polly Toynbee about Donald Trump’s complaints about NHS pricing

The Guardian - UK

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

The Guardian - UK

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

The Guardian - UK

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

Evening Standard

Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain

The NHS needs cheap drugs, and our economy needs a thriving pharma industry. The president threatens both – no wonder Labour is grovelling to him, says Guardian columnist Polly Toynbee

The Guardian - UK

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Pharmacy leaders issue warning over ‘dangerous’ medicine delays

One pharmacist reported their patients waiting more than a week for a medication for bipolar and schizophrenia

The Guardian - UK

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

Investors Business Daily

Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout

Monopar Therapeutics unveiled promising results Monday from three key studies, leading the top 1% biotech stock to break out of a cup base.

The Independent UK

Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site

The investment had been set to create 1,000 jobs

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca pauses £200m investment in Cambridge research site

Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding

Axios

Exclusive: Lutnick says Trump will force drugmakers to lower prices

Trump's efforts include reshaping drug prices through threats and public shaming.

The Guardian - UK

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments

The Guardian - UK

UK must heed Sir John Bell’s big pharma investment warning

Instead of making silly statements the government needs to look at why Merck has scrapped its £1bn research centre

Investors Business Daily

AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day

AbbVie stock broke out Thursday after the pharma announced it had entered a deal that will stave off generic Rinvoq until April 2037.

The Independent UK

Pharma giant ditches £1bn London research hub and says UK ‘is not internationally competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

The Guardian - UK

Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit

Comments by former professor of medicine at Oxford follow scrapping of planned London research centre

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.